Search | Clinical Trials Finder

Conditions: Asthma
Interventions: Placebo, Dupilumab SAR231893/REGN668, fluticasone propionate and salmeterol, budesonide and formoterol, mometasone furoate and formoterol; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 6
States / cities: Tucson, Arizona • Denver, Colorado • Boston, Massachusetts + 3 more

Conditions: Asthma
Interventions: Symbicort; Drug
Lead sponsor: Stanford University; Other
Eligibility: 12 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Stanford, California

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: BGF; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years and older
Enrollment: 13,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Wilmington, Delaware

Conditions: COPD (Chronic Obstructive Pulmonary Disease)
Interventions: BGF MDI 320/14.4/9.6 μg, GFF MDI 14.4/9.6 μg; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 229
States / cities: Athens, Alabama • Cullman, Alabama • Fairhope, Alabama + 189 more

Conditions: Asthma
Interventions: Budesonide/Formoterol fumarate dihydrate, Symbicort, Placebo; Drug
Lead sponsor: Kindeva Drug Delivery; Industry
Eligibility: 18 Years and older
Enrollment: 1,762 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 95
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 74 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: BGF, MITT; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years and older
Enrollment: 22,369 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Wilmington, Delaware

Conditions: COPD
Interventions: BGF MDI 320/14.4/9.6 μg, GFF MDI (PT003) 14.4/9.6 μg, BFF MDI (PT009) 320/9.6 μg, Symbicort® Turbuhaler® (TBH) Inhalation Powder; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 1,902 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 63
States / cities: Andalusia, Alabama • Jasper, Alabama • Peoria, Arizona + 54 more

Conditions: COPD Patients
Interventions: Symbicort, Formoterol turbohaler, Placebo for Symbicort pMDI, Placebo for Formoterol Turbohaler; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 95 Years
Enrollment: 2,026 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 224
States / cities: Andalusia, Alabama • Birmingham, Alabama • Foley, Alabama + 107 more

Conditions: Asthma
Interventions: Lunsekimig, Short-Acting Beta Agonists (SABA), Placebo, Fluticasone/Salmeterol, Budesonide/Formoterol, Budesonide/Albuterol; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 556 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 54
States / cities: Saraland, Alabama • Chandler, Arizona • Sun City, Arizona + 48 more

Conditions: Chronic Obstructive Lung Disease
Interventions: Budesonide, Symbicort; Drug
Lead sponsor: Columbia University; Other
Eligibility: 40 Years to 75 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: BGF- BUDESONIDE/GLYCOPYRRONIUM/FORMOTEROL; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years and older
Enrollment: 3,598 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Gaithersburg, Maryland

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Budesonide 160 mcg and formoterol fumarate dihydrate 4.5 mcg Inhalation aerosol, Matching Placebo pMDI 160/4.5 μg; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 5
States / cities: Hartford, Connecticut • Boston, Massachusetts • Charlotte, North Carolina + 2 more

Conditions: Asthma
Interventions: Symbicort pMDI, Budesonide pMDI; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 882 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 59
States / cities: Hoover, Alabama • Montgomery, Alabama • Gilbert, Arizona + 56 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Treatment A (BGF MDI HFO with oral activated charcoal), Treatment B (BGF MDI HFA with oral activated charcoal); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: COPD (Chronic Obstructive Pulmonary Disease)
Interventions: BGF MDI HFO 320/14.4/9.6μg, BGF MDI HFA 320/14.4/9.6 μg, Placebo MDI HFA; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 297 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 19
States / cities: Sheffield, Alabama • Clearwater, Florida • Gainesville, Florida + 16 more

Conditions: Chronic Obstructive Pulmonary Disorder
Interventions: BFF MDI (PT009) 320/9.6 μg, BFF MDI (PT009) 160/9.6 μg, FF MDI (PT005) 9.6 μg; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 1,876 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 121
States / cities: Dothan, Alabama • Huntsville, Alabama • Sheffield, Alabama + 107 more

Conditions: Pneumonia, Hypoxemia, Acute Respiratory Failure, COVID-19 Pneumonia
Interventions: Inhaled budesonide and formoterol, Inhaled placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 465 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 12
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 8 more

Conditions: Asthma
Interventions: BGF MDI 320/28.8/9.6 μg, BGF MDI 320/14.4/9.6 μg, BFF MDI 320/9.6 μg, BFF pMDI 320/9 μg; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 80 Years
Enrollment: 2,274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 107
States / cities: Saraland, Alabama • Phoenix, Arizona • Sun City West, Arizona + 96 more

Conditions: Asthma
Interventions: Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg, Symbicort, 80 Mcg-4.5 Mcg/Inh Inhalation Aerosol, Placebo; Drug
Lead sponsor: Cipla Ltd.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 1,485 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Medford, Oregon

Conditions: Asthma
Interventions: Budesonide/formoterol fumarate Aerosphere, Budesonide/formoterol fumarate pMDI; Combination Product
Lead sponsor: AstraZeneca; Industry
Eligibility: 4 Years to 12 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 6
States / cities: Long Beach, California • Miami, Florida • Lafayette, Louisiana + 3 more

Conditions: Asthma
Interventions: Tiotropium, Salmeterol, Formoterol; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 1,070 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 13
States / cities: Jacksonville, Florida • Marietta, Georgia • Newton, Georgia + 10 more

Conditions: Asthma
Interventions: Dupilumab, placebo, ICS/LABA therapy, Salbutamol/albuterol, Levosalbutamol/levalbuterol; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 776 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 50
States / cities: Fullerton, California • Huntington Beach, California • Los Angeles, California + 38 more

Conditions: Asthma
Interventions: BFF MDI 320/9.6 μg, BFF MDI 160/9.6 μg, BD MDI 320 μg, Open-label Symbicort TBH 320/9 μg; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 80 Years
Enrollment: 645 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 66
States / cities: Chandler, Arizona • Tucson, Arizona • Bakersfield, California + 56 more

Conditions: Asthma
Interventions: budesonide/formoterol, fluticasone/salmeterol, mometasone/formoterol, Prednisone; Drug
Lead sponsor: Gelb, Arthur F., M.D.; Individual
Eligibility: 10 Years to 95 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2027
U.S. locations: 1
States / cities: Lakewood, California

Search by objective public record fields.

Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma

Use of Symbicort or Pulmicort to Treat Viral-mediated Asthma Exacerbations

EXACERBATIONS AND REAL-WORLD OUTOMES INCLUDING CARDIOPULMONARY EVENTS AMONG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (MITOS: EROS+CP US Study)

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

Randomized, Placebo-controlled, Multi-dose, Study Comparing Budesonide/Formoterol to Symbicort® in Asthmatic Patients

A Comparative Effectiveness Study of Mortality Outcomes and Related Cardiopulmonary Events Among a Cohort of Chronic Obstructive Pulmonary Disease (COPD) Patients Who Initiate Breztri and Multiple Inhaler Triple Therapy (MITT) in the United States (US)

A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos)

Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease

Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma

Effects of Symbicort on the Ventilatory Kinematics

Exacerbations and Real-World Outcomes Among Patients With Chronic Obstructive Pulmonary Disease Following Severe Exacerbation

Phase IV O2 Consumption Study in COPD Patients.

A 12-Week Study in Asthmatic Children Ages 6 to <12 Years, Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared With Budesonide pMDI 80 μg

Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant

A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation Propellant in Participants 40 to 80 Years of Age With COPD

A Study to Assess the Efficacy and Safety of PT009 Compared to PT005 on COPD Exacerbations Over a 52-Week Period in Subjects With Moderate to Very Severe COPD (Sophos)

ARrest RESpiraTory Failure From PNEUMONIA

Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)

BE Study Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg Inhalation Product in Asthma Patient

A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With Asthma

Blacks and Exacerbations on Long Acting Beta Agonists (LABA) vs. Tiotropium (BELT)

An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma

A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma (VATHOS)

Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma